<unk>  is an antineoplastic agent that is FDA approved for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include pyrexia, headache , peripheral edema , febrile neutropenia , nausea , hypokalemia , and constipation  and the most common serious adverse reactions  included febrile neutropenia, pyrexia, pneumonia, sepsis, neutropenia, device-related infection, tremor, encephalopathy, infection, overdose, confusion, Staphylococcal bacteremia, and headache..
Blinatumomab
Bavituximab
Volociximab
Tositumomab
Dinutuximab
Adecatumumab
Daratumumab
Abiciximab